Company Filing History:
4 out of 80 
2 out of 50 
1 out of 83 Years Active: 2013-2019
Title: Kiwamu Imagawa: Innovator in Corneal Cell Culture Technologies
Introduction
Kiwamu Imagawa is a notable inventor based in Hyogo, Japan, recognized for his contributions to the field of regenerative medicine, particularly in the production of human corneal epithelial sheets. With a total of four patents to his name, Imagawa has made significant strides in developing methods that enhance the cultivation of corneal cells for therapeutic applications.
Latest Patents
Imagawa's latest patents include a method for producing human corneal epithelium sheets. This innovative approach addresses the challenge of culturing human corneal epithelial-derived cells on an amnion substrate. The solution involves using mesenchymal stem cells as feeder cells and employing a medium that contains a combination of a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor, and a TGF-β receptor inhibitor. Another significant patent focuses on a medium for culturing corneal endothelial cells, which utilizes conditioned medium from mesenchymal stem cells. This method aims to maintain the morphology of corneal endothelial cells while preparing them for transplantation in patients suffering from corneal endothelial failure.
Career Highlights
Throughout his career, Kiwamu Imagawa has worked with esteemed organizations such as JCR Pharmaceuticals Co., Ltd. and Kyoto Prefectural Public University Corporation. His work in these institutions has allowed him to collaborate with other experts in the field and contribute to advancements in cell culture technologies.
Collaborations
Imagawa has collaborated with notable colleagues, including Noriko Koizumi and Naoki Okumura, who have played a role in his research endeavors. Their combined expertise has furthered the development of innovative solutions in regenerative medicine.
Conclusion
Kiwamu Imagawa's work in the field of corneal cell culture represents a significant advancement in regenerative medicine. His innovative methods and collaborations have the potential to improve treatment options for patients with corneal conditions.